Jihwan Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jihwan Yoo has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Jong Hee Chang
Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
11 shared publications - Seok-Gu Kang
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
10 shared publications - Eui Hyun Kim
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
6 shared publications Hun Ho Park
Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Republic of Korea
5 shared publications- Hun Ho Park
Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
5 shared publications - Hyun Kim
Department of Anatomy and Brain Korea 21 Graduate Program, Biomedical Science, College of Medicine, Korea University, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Elsevier in Brain and Spine
- Vol. 6, 106158
Clinical outcomes and survival benefits of craniotomy in breast cancer patients with brain metastases: Focusing on candidate selection and early mortality
- 7 July 2026
- Published by Elsevier in Brain and Spine
- Vol. 6, 106158
Open AccessClinical outcomes and survival benefits of craniotomy in breast cancer patients with brain metastases: Focusing on candidate selection and early mortality
- Open Access
- 15 January 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (1) , 182-197
Spatial Transcriptomic Landscape of Brain Metastases from Triple-Negative Breast Cancer: Comparison of Primary Tumor and Brain Metastases Using Spatial Analysis
Purpose Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, with approximately 30% of patients eventually developing brain metastases (BM), which result in poor outcomes. An understanding of the tumor microenvironment (TME) at both primary and metastatic sites offers insights into the mechanisms underlying BM and potential therapeutic targets.Materials and Methods Spatial RNA sequencing (spRNA-seq) was performed on primary TNBC and paired BM tissues from three patients, one of whom had previously received immune checkpoint inhibitors before BM diagnosis. Specimen regions were categorized into tumor, proximal, and distal TME based on their spatial locations. Gene expression differences across these zones were analyzed, and immune cell infiltration was estimated using TIMER. A gene module analysis was conducted to identify key gene clusters associated with BM.Results Distinct gene expression profiles were noted in the proximal and distal TMEs. In BM, the proximal TME exhibited neuronal gene expression, suggesting neuron-tumor interactions compared to tumor, and upregulation of epithelial genes compared to the distal TME. Immune cell analysis revealed dynamic changes in CD8+ T cells and macrophages across the tumor and TME zones. Gene module analysis identified five key modules, including one related to glycolysis, which correlated with patient survival. Drug repurposing analysis identified potential therapeutic targets, including VEGFA, RAC1, EGLN3, and CAMK1D.Conclusion This study provides novel insights into the transcriptional landscapes in TNBC BM using spRNA-seq, emphasizing the role of neuron-tumor interactions and immune dynamics. These findings suggest new therapeutic strategies and underscore the importance of further research.
- 15 January 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (1) , 182-197
Open AccessSpatial Transcriptomic Landscape of Brain Metastases from Triple-Negative Breast Cancer: Comparison of Primary Tumor and Brain Metastases Using Spatial Analysis
Purpose Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, with approximately 30% of patients eventually developing brain metastases (BM), which result in poor outcomes. An understanding of the tumor microenvironment (TME) at both primary and metastatic sites offers insights into the mechanisms underlying BM and potential therapeutic targets.Materials and Methods Spatial RNA sequencing (spRNA-seq) was performed on primary TNBC and paired BM tissues from three patients, one of whom had previously received immune checkpoint inhibitors before BM diagnosis. Specimen regions were categorized into tumor, proximal, and distal TME based on their spatial locations. Gene expression differences across these zones were analyzed, and immune cell infiltration was estimated using TIMER. A gene module analysis was conducted to identify key gene clusters associated with BM.Results Distinct gene expression profiles were noted in the proximal and distal TMEs. In BM, the proximal TME exhibited neuronal gene expression, suggesting neuron-tumor interactions compared to tumor, and upregulation of epithelial genes compared to the distal TME. Immune cell analysis revealed dynamic changes in CD8+ T cells and macrophages across the tumor and TME zones. Gene module analysis identified five key modules, including one related to glycolysis, which correlated with patient survival. Drug repurposing analysis identified potential therapeutic targets, including VEGFA, RAC1, EGLN3, and CAMK1D.Conclusion This study provides novel insights into the transcriptional landscapes in TNBC BM using spRNA-seq, emphasizing the role of neuron-tumor interactions and immune dynamics. These findings suggest new therapeutic strategies and underscore the importance of further research.
- Top Cited Papers
- 8 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6781) , eadt0559
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level IDH mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type–specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial IDH mutation were responsible for the development of IDH-mutant gliomas.
- 8 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6781) , eadt0559
Top Cited PapersIDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level IDH mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type–specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial IDH mutation were responsible for the development of IDH-mutant gliomas.
- Open Access
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (3) , 159-163
Glioblastoma in a Patient With MELAS Syndrome: A Case Report
Chang SM, et al. Brain Tumor Res Treat. 2026 Jul;14(3):159-163. https://doi.org/10.14791/btrt.2026.0015
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (3) , 159-163
Open AccessGlioblastoma in a Patient With MELAS Syndrome: A Case Report
Chang SM, et al. Brain Tumor Res Treat. 2026 Jul;14(3):159-163. https://doi.org/10.14791/btrt.2026.0015
- Open Access
- 19 November 2025
- Published by Elsevier in The Breast
- Vol. 85, 104650
Impact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis
- 19 November 2025
- Published by Elsevier in The Breast
- Vol. 85, 104650
Open AccessImpact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression
Purpose:Clinical trials have shown limited efficacy of anti–PD-1 treatment for glioblastoma (GBM). In this study, we examined the expression of TGFβ type I receptor (TGFβRI) in GBM-infiltrating CD8+ T cells and the characteristics of TGFβRI+CD8+ T cells. We examined the ex vivo effects of the co-blockade of PD-1 and TGFβ on the functions of GBM-infiltrating CD8+ T cells.Experimental Design:Using flow cytometry, we examined the phenotypes of tumor-infiltrating CD8+ T cells from newly diagnosed patients with GBM. We performed single-cell RNA/T-cell receptor sequencing to characterize the tumor-infiltrating TGFβRI+CD8+ T cells. We also examined the effects of co-blockade of PD-1 and TGFβ on the functions of tumor-infiltrating CD8+ T cells in ex vivo assays.Results:GBM-infiltrating CD8+ T cells expressed significantly increased levels of TGFβRI compared with peripheral blood CD8+ T cells. Among tumor-infiltrating CD8+ T cells, TGFβRI+CD8+ T cells exhibited increased expression of immune checkpoint inhibitory receptors, and tumor antigen–specific cells were enriched in TGFβRI+CD8+ T cells. Single-cell profiling revealed that tumor-infiltrating TGFBR1+CD8+ T cells demonstrated more clonal expansion and upregulation of T-cell receptor signaling genes compared with TGFBR1−CD8+ T cells. In vitro, anti-CD3 stimulation upregulated TGFβRI expression on CD8+ T cells. Patients with GBM with a high frequency of TGFβRI+CD8+ T cells presented with increased TGFβ signaling intensity. Importantly, combined blockade of PD-1 and TGFβ significantly enhanced the functions of tumor-infiltrating CD8+ T cells ex vivo.Conclusions:Our findings provide a basis for further investigation of the co-blockade of PD-1 and TGFβ for the treatment of patients with GBM.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression
Purpose:Clinical trials have shown limited efficacy of anti–PD-1 treatment for glioblastoma (GBM). In this study, we examined the expression of TGFβ type I receptor (TGFβRI) in GBM-infiltrating CD8+ T cells and the characteristics of TGFβRI+CD8+ T cells. We examined the ex vivo effects of the co-blockade of PD-1 and TGFβ on the functions of GBM-infiltrating CD8+ T cells.Experimental Design:Using flow cytometry, we examined the phenotypes of tumor-infiltrating CD8+ T cells from newly diagnosed patients with GBM. We performed single-cell RNA/T-cell receptor sequencing to characterize the tumor-infiltrating TGFβRI+CD8+ T cells. We also examined the effects of co-blockade of PD-1 and TGFβ on the functions of tumor-infiltrating CD8+ T cells in ex vivo assays.Results:GBM-infiltrating CD8+ T cells expressed significantly increased levels of TGFβRI compared with peripheral blood CD8+ T cells. Among tumor-infiltrating CD8+ T cells, TGFβRI+CD8+ T cells exhibited increased expression of immune checkpoint inhibitory receptors, and tumor antigen–specific cells were enriched in TGFβRI+CD8+ T cells. Single-cell profiling revealed that tumor-infiltrating TGFBR1+CD8+ T cells demonstrated more clonal expansion and upregulation of T-cell receptor signaling genes compared with TGFBR1−CD8+ T cells. In vitro, anti-CD3 stimulation upregulated TGFβRI expression on CD8+ T cells. Patients with GBM with a high frequency of TGFβRI+CD8+ T cells presented with increased TGFβ signaling intensity. Importantly, combined blockade of PD-1 and TGFβ significantly enhanced the functions of tumor-infiltrating CD8+ T cells ex vivo.Conclusions:Our findings provide a basis for further investigation of the co-blockade of PD-1 and TGFβ for the treatment of patients with GBM.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM.Significance:We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression.See related commentary by Lee and Suvà, p. 1312
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM.Significance:We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression.See related commentary by Lee and Suvà, p. 1312
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Supplementary Figure S1. Enrichment of mutation-harboring cells during GBM evolution in the spontaneous GBM mouse model. Supplementary Figure S2. The quality control and pre-processing of single-cell RNA-seq data. Supplementary Figure S3. Characterization of unknown cell clusters. Supplementary Figure S4. Classification of precancerous and cancer cell clusters with associated gene modules. Supplementary Figure S5. Classification of precancerous and cancer cell clusters using single-cell multiome sequencing. Supplementary Figure S6. Classification of cancer cell clusters using single-cell RNA sequencing. Supplementary Figure S7. Changes in cell-cell interaction analyses between precancer and cancer stages. Supplementary Figure S8. Fluorescent in situ hybridization of precancerous cell markers. Supplementary Figure S9. Proliferation analysis after Gap43 and Ccnd1 siRNA treatment. Supplementary Figure S10. Clinical characteristics of GBM patients. Supplementary Figure S11. Single-cell analysis of SVZ and tumor from each patient. Supplementary Figure S12. Characterization of human cell types and unknown cell population. Supplementary Figure S13. Variant allele frequencies of driver mutations. Supplementary Figure S14. Copy number analysis for Pre-CC and CC in patient #1. Supplementary Figure S15. Copy number analysis for Pre-CC and CC in patient #2.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Supplementary Figure S1. Enrichment of mutation-harboring cells during GBM evolution in the spontaneous GBM mouse model. Supplementary Figure S2. The quality control and pre-processing of single-cell RNA-seq data. Supplementary Figure S3. Characterization of unknown cell clusters. Supplementary Figure S4. Classification of precancerous and cancer cell clusters with associated gene modules. Supplementary Figure S5. Classification of precancerous and cancer cell clusters using single-cell multiome sequencing. Supplementary Figure S6. Classification of cancer cell clusters using single-cell RNA sequencing. Supplementary Figure S7. Changes in cell-cell interaction analyses between precancer and cancer stages. Supplementary Figure S8. Fluorescent in situ hybridization of precancerous cell markers. Supplementary Figure S9. Proliferation analysis after Gap43 and Ccnd1 siRNA treatment. Supplementary Figure S10. Clinical characteristics of GBM patients. Supplementary Figure S11. Single-cell analysis of SVZ and tumor from each patient. Supplementary Figure S12. Characterization of human cell types and unknown cell population. Supplementary Figure S13. Variant allele frequencies of driver mutations. Supplementary Figure S14. Copy number analysis for Pre-CC and CC in patient #1. Supplementary Figure S15. Copy number analysis for Pre-CC and CC in patient #2.